Compare Dr. Reddys with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GSK PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GSK PHARMA DR. REDDYS LAB/
GSK PHARMA
 
P/E (TTM) x 32.5 211.1 15.4% View Chart
P/BV x 4.6 10.9 42.1% View Chart
Dividend Yield % 0.5 1.5 35.5%  

Financials

 DR. REDDYS LAB   GSK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
GSK PHARMA
Mar-19
DR. REDDYS LAB/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,8753,595 80.0%   
Low Rs1,8881,253 150.7%   
Sales per share (Unadj.) Rs930.2184.7 503.8%  
Earnings per share (Unadj.) Rs117.426.3 446.6%  
Cash flow per share (Unadj.) Rs185.829.2 637.0%  
Dividends per share (Unadj.) Rs20.0020.00 100.0%  
Dividend yield (eoy) %0.80.8 101.8%  
Book value per share (Unadj.) Rs844.4126.3 668.5%  
Shares outstanding (eoy) m166.07169.40 98.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.613.1 19.5%   
Avg P/E ratio x20.392.2 22.0%  
P/CF ratio (eoy) x12.883.1 15.4%  
Price / Book Value ratio x2.819.2 14.7%  
Dividend payout %17.076.1 22.4%   
Avg Mkt Cap Rs m395,496410,626 96.3%   
No. of employees `00022.05.0 442.9%   
Total wages/salary Rs m33,5625,372 624.8%   
Avg. sales/employee Rs Th7,032.86,306.7 111.5%   
Avg. wages/employee Rs Th1,527.91,083.1 141.1%   
Avg. net profit/employee Rs Th887.7898.0 98.9%   
INCOME DATA
Net Sales Rs m154,48231,281 493.8%  
Other income Rs m3,3751,023 329.9%   
Total revenues Rs m157,85732,304 488.7%   
Gross profit Rs m31,7826,009 528.9%  
Depreciation Rs m11,348486 2,335.0%   
Interest Rs m8896 14,816.7%   
Profit before tax Rs m22,9206,540 350.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m3,8582,373 162.6%   
Profit after tax Rs m19,5004,454 437.8%  
Gross profit margin %20.619.2 107.1%  
Effective tax rate %16.836.3 46.4%   
Net profit margin %12.614.2 88.7%  
BALANCE SHEET DATA
Current assets Rs m111,10120,061 553.8%   
Current liabilities Rs m58,97314,543 405.5%   
Net working cap to sales %33.717.6 191.3%  
Current ratio x1.91.4 136.6%  
Inventory Days Days7957 139.8%  
Debtors Days Days9414 670.0%  
Net fixed assets Rs m101,24514,343 705.9%   
Share capital Rs m8301,694 49.0%   
"Free" reserves Rs m139,40619,704 707.5%   
Net worth Rs m140,23621,398 655.4%   
Long term debt Rs m22,0002 1,100,000.0%   
Total assets Rs m224,65639,113 574.4%  
Interest coverage x26.81,091.0 2.5%   
Debt to equity ratio x0.20 167,846.5%  
Sales to assets ratio x0.70.8 86.0%   
Return on assets %9.111.4 79.6%  
Return on equity %13.920.8 66.8%  
Return on capital %14.931.9 46.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,673534 16,605.4%   
Fx outflow Rs m19,1047,091 269.4%   
Net fx Rs m69,569-6,557 -1,061.0%   
CASH FLOW
From Operations Rs m28,7043,994 718.7%  
From Investments Rs m-7,727-1,433 539.1%  
From Financial Activity Rs m-21,326-3,584 595.1%  
Net Cashflow Rs m-314-1,023 30.7%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 5.4 10.2 52.9%  
FIIs % 35.3 23.8 148.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 15.4 99.4%  
Shareholders   75,885 102,036 74.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  ABBOTT INDIA  PANACEA BIOTECH  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Crude Oil Sees Buying, FPI Equity Inflows Rise, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended marginally lower yesterday as benchmark indices gave up early gains and slipped into the red during the last hour of trading.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


May 26, 2020 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS